12:00 AM
Jul 13, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FST-100: Phase II started

Foresight began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate topical FST100 given 4 times daily...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >